🔎 Trials Near Me

Akèy › Lukemi lenfositè kwonik › Virginia

Etid klinik pou Lukemi lenfositè kwonik nan Virginia

12 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan Virginia.

Vil nan Virginia

Tèks ofisyèl etid la (Anglè)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • VCU Massey Comprehensive Cancer Center, Richmond
  • VCU Health Tappahannock Hospital, Tappahannock
Ap rekriteFaz 3
Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Chesapeake Regional Medical Center, Chesapeake
  • Augusta Health Center for Cancer and Blood Disorders, Fishersville
  • Bon Secours Memorial Regional Medical Center, Mechanicsville
  • ak 7 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Ballad Health Cancer Care - Bristol, Bristol
  • Ballad Health Cancer Care - Norton, Norton
  • VCU Massey Cancer Center at Stony Point, Richmond
  • ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04269902

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Virginia Commonwealth University Massey Cancer Center, Richmond
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia), Roanake
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06973187

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  • University of Virginia Cancer Center ( Site 5402), Charlottesville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05947851

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • University of Virginia Cancer Center ( Site 0040), Charlottesville
  • Inova Schar Cancer Institute ( Site 0015), Fairfax
  • Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • Virginia Cancer Specialists, PC, Fairfax
  • Oncology & Hematology Associates of Southwest VA, Norfolk
  • Virginia Oncology Associates, Norfolk
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07221500

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

  • Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT07516093

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • Virginia Cancer Institute, Richmond
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • USO-Virginia Oncology Associates, Hampton
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 19, 2026 · NCT06588478

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.